CNS Pharmaceuticals, Inc. (CNSP) Research

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.

Market snapshot

Symbol
CNSP
Price
$4.70
Day change
+3.75%
Market cap
$2.7M
P/E ratio
-0.19x
52-week range
1.9-12.36
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$0.50

Recent news

  • What's Going On With CNS Pharmaceuticals Stock On Wednesday?

    CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Wednesday's premarket session.

  • Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot

    CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Monday's premarket session following the announcement of an oversubscribed private placement financing expected to generate approximately $22.5 million.

Peer companies

  • Clearmind Medicine Inc. (CMND)
  • Ensysce Biosciences, Inc. (ENSC)
  • GRI Bio, Inc. (GRI)
  • Pasithea Therapeutics Corp. (KTTA)
  • NLS Pharmaceutics AG (NLSP)
  • Oragenics, Inc. (OGEN)
  • Silo Pharma, Inc. (SILO)
  • Soligenix, Inc. (SNGX)

Recent insider activity

  • Charles Faith L. — P-Purchase (7100 shares) on 2026-05-18
  • Faulkner Eric — A-Award (9500 shares) on 2026-03-02
  • Faulkner Eric — trade (0 shares) on 2026-03-02
  • O'Loughlin Steve — A-Award (9500 shares) on 2026-03-02
  • O'Loughlin Steve — trade (0 shares) on 2026-03-02

Open CNS Pharmaceuticals, Inc. (CNSP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.